Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Medical Inc.

Division of Abbott Laboratories Inc.
www.sjm.com

Latest From St. Jude Medical Inc.

MTI 100: Major M&A Bookends Year Of Mainly Steady Growth For Leading Medtech Groups

In Medtech Insight's latest rankings of top 100 revenue-earners in the medical device and diagnostics sector, it was steady as she goes for most of the multinational medtechs, with some major exceptions. But there will be more M&A reflected in next year's ranking based on 2018 revenues. Also, medtech groups leading the global market tightened their grip further in 2017, as providers chose to partner more and more with fewer suppliers who can offer a wider provision of services.

Commercial M & A

Market Access Knowhow Keeps Strategic Medtechs Ahead Of The Game

European markets are notoriously complex for medtech companies that are just setting out their market access strategies. But the fragmented reimbursement scenario should not deter companies, large and small, from putting time into a solid strategy, and allocating the correct budget and resources.

Market Access Medical Device

HRS 2018 Wrap-Up: Tendril Lead Failures; Metaanalysis Of Contact-Force Catheter; LuxCath's OmniView; More Micra Results

The 2018 Heart Rhythm Society scientific sessions in Boston covered a variety of presentations of new electrophysiology clinical data, including a report on the failure of St. Jude's Tendril leads, a meta-analysis of contact-force catheters for atrial-fibrillation ablation, and new data on Medtronic's Micra leadless pacemaker.

Cardiology Clinical Trials

HRS 2018: CABANA Misses Endpoint, Leaving Questions About AF Ablation

The long-awaited results of the CABANA trial, a large randomized study comparing ablation to drug therapy as a first-line treatment for atrial fibrillation, were presented at the Heart Rhythm Society conference in Boston on May 10. The trial missed its primary endpoint in the "intent to treat" analysis, but showed a significant benefit for ablation in the "as-treated" analysis.

Cardiovascular Cardiology
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register